2020 Fatigue Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

2020 Fatigue Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

  • February 2020 •
  • 42 pages •
  • Report ID: 5863892 •
  • Format: PDF
The 2020 Fatigue pipeline report presents a comprehensive overview of the research and development of Fatigue drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Pre-clinical phase, one drug in Phase 1, and three drugs in Phase 2

As of February 2020, the Fatigue pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Fatigue treatment. Diverse types of targeted therapies are being explored through clinical trials including thyrotropin releasing hormone receptor (TRHR) agonist; Adrenergic uptake inhibitor; dopamine transporter inhibitor; Dopamine uptake inhibitor; ghrelin receptor agonist; noradrenaline transporter inhibitor.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Fatigue drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

Publisher Expertise
Our online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

Scope:
• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Fatigue development
• Fatigue pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Fatigue pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Fatigue pipeline candidates included
• Business overview and snapshot of all companies involved in Fatigue pipeline are included
• Latest market and pipeline developments are provided in the report

Fatigue pipeline companies included in the report are- Chronos Therapeutics, Helsinn Group, K-Pax Pharmaceuticals Inc, Merz Pharma GmbH & Co KgaA, MultiCell Technologies Inc, Primetime Life Sciences LLC, Resolys Bio Inc

Fatigue pipeline drugs profiled in the report include- MS CTDP-001, anamorelin (ONO-7643), KPAX002, MRZ-9547, MCT-125(lofepramine + phenylalanine), PLS-4, Tissue based Chronic Pain and Fatigue